Are you confused about Obamacare? KQED and The California Report created a guide to help answer your questions about the Affordable
Care Act.
Recent cuts to Bay Area public transit may be affecting some riders’ long-term health.
In a unanimous decision, the U.S. Supreme Court decided this week that human genes cannot be patented. A biotech company, Myriad Genetics, held patents on two genes linked to breast and ovarian cancer. But the Court ruled that because the company had simply isolated the genes and had not synthetically created something new, the patents were not valid. The company argued that allowing patents on human genes incentivizes research. But critics said it would hamper science by raising the cost of testing. What does the decision mean for medical and scientific research?
California's multi-billion-dollar biotech industry is taking in Thursday's landmark Supreme Court ruling on human genes. In short, naturally occurring genes are not patentable. It's a major shift for biotech companies -- but it's one they're prepared for.